Investigators synthesized observational evidence on prenatal exposure to antipsychotics and antidepressants and the subsequent risk of gestational diabetes. They identified 21 eligible studies from PubMed, Scopus, and Web of Science through June 2025 and pooled adjusted relative risks (RRs) using a random-effects model. The combined analysis for women exposed to any antipsychotics and antidepressants produced a pooled adjusted RR of 1.43 (95% CI: 1.17–1.69). A separate pooled estimate for antidepressants alone was 1.19 (95% CI: 1.10–1.27). Short, clear result: exposure to these commonly prescribed psychotropics during pregnancy was associated with a measurable increase in GDM risk in the pooled data.
The abstract lists these pooled RRs and confidence intervals as the core quantitative findings. The study team reported subgroup analyses by medication classification; further details on study-level covariates and heterogeneity measures were not included in the abstract and thus are not available here.
The review disaggregated antipsychotics by generation. Data indicated that second-generation antipsychotics (SGAs) were associated with a higher risk of gestational diabetes (RR = 1.6, 95% CI: 1.23–1.97). First-generation antipsychotics did not show a statistically significant association with GDM in the pooled analysis. The authors reported these class-specific differences directly; they did not provide drug-by-drug RRs, exposure timing windows, or dosing information in the abstract, which the source did not report.
This differential signal—higher risk with SGAs but not FGAs—matches concerns clinicians have about metabolic adverse effects linked to several agents in the second-generation class. The study team observed the association at the class level, not as definitive proof for individual molecules.
The authors conducted a systematic search of three bibliographic databases (PubMed, Scopus, Web of Science) up to June 2025 to identify observational studies reporting GDM outcomes after prenatal psychotropic exposure. Eligible observational designs were included and pooled using a random-effects model. Pooled adjusted RRs were the primary quantitative synthesis metric. Subgroup analyses were performed according to medication classification (antidepressant versus antipsychotic classes).
Specifics that the abstract did not report include the number of cohort versus case-control studies, individual study sample sizes, covariates used in adjusted models across studies, measures of between-study heterogeneity (for example I2), and any assessment of publication bias. Those methodological details are present in the full paper but were not provided in the abstract text cited here.
The authors framed their findings in clinical terms: prenatal exposure to antipsychotics—particularly SGAs—and to antidepressants is associated with an increased risk of gestational diabetes. They recommended that clinicians weigh metabolic risks when prescribing psychotropic medications during pregnancy and ensure appropriate metabolic monitoring for pregnant women receiving these agents. Briefly: management decisions should balance maternal psychiatric needs with metabolic surveillance strategies.
The abstract does not specify monitoring protocols, frequency of glucose testing, or thresholds for changing therapy; the authors called for clinicians to consider risk and monitoring rather than issuing prescriptive monitoring algorithms.
The review used previously published observational data only; therefore ethics approval and trial registration were not applicable. The authors declared no competing interests. The abstract acknowledges increased GDM risk associated with psychotropic exposure but does not present granular methodological metrics in the summary provided here. Consequently, remaining questions include the degree to which residual confounding affected pooled estimates, how exposure timing (trimester-specific use) might modify risk, whether risks differ between individual drugs within antidepressant and SGA classes, and what the absolute risk increase is for different baseline-risk populations. Those unresolved items were not reported in the abstract and would require full-text examination.
Clinicians and guideline panels should note the pooled associations and consider metabolic monitoring when psychotropic therapy is continued in pregnancy. The authors’ final statements call for careful prescribing and monitoring but stop short of specific clinical pathways; that gap remains an outstanding question documented in the source abstract.